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ABSTRACT. Low birth weight (LBW) infants have increased susceptibility to perinatal complications. An
immature and impaired vascular system may possibly participate in these complications. There is evidence that
supports the notion that vascular endothelial growth factor (VEGF), which is an essential regulator of embryonic
angiogenesis, plays a central role in the pathogenesis of perinatal complications. We aimed to test whether
functional genetic polymorphisms of VEGF are associated with the risk of preterm birth or perinatal morbidity.
We enrolled 128 LBW infants (≤ 1500 grams). VEGF T-460C, VEGF C-2578A and VEGF G+405C polymorphisms
were determined by real-time PCR or PCR-RFLP, respectively. Their genotypes were compared with VEGF
genotypes of 200 healthy, term neonates. The prevalence of the VEGF+405 C allele was higher in LBW infants
than in healthy, term neonates (OR [95% CI]: 1.29 [1.01-1.65]). Carrier state for the VEGF -2578A allele was an
independent risk factor for enterocolitis necrotisans (NEC) (adjusted OR [95% CI]: 2.77 [1.00-7.65]). The carrier
state for the VEGF -2578AA genotype was associated with a decreased risk of acute renal failure (ARF) (adjusted
OR [95% CI]: 0.2 [0.05-0.78]). These results suggest that VEGF G+405C polymorphism might be associated with
a higher risk of preterm birth and that VEGF C-2578A polymorphism may participate in the development of
perinatal complications such as NEC and ARF.
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In industrialized countries, 5-11% of infants are born pre-
term (< 37 weeks’ gestation), and because of perinatal
complications, preterm births account for up to 75% of
neonatal morbidity [1].
In LBW infants, the immature and impaired vascular sys-
tem plays a central role in the pathogenesis of the most
common perinatal complications such as intraventricular
hemorrhage (IVH), retinopathy of prematurity (ROP),
congenital heart disease, bronchopulmonary dysplasia
(BPD) [2], acute renal failure (ARF) [3] and enterocolitis
necrotisans (NEC) [4].
The significance of vascular endothelial growth factor
(VEGF) has been recognized in the pathogenesis of these
perinatal complications. VEGF is a potent vascular perme-
ability and angiogenic factor which regulates multiple
endothelial cell functions, such as apoptosis and synthesis
of nitric oxide and prostacyclin [5].
A significant association was demonstrated between con-
centrations of VEGF in cerebrospinal fluid and the devel-
opment of post-hemorrhagic hydrocephalus after severe
IVH [6]. It was observed that during the first phase of ROP,
the production of VEGF was decreased [7], while it was
increased during the second, proliferative, phase of the
disease [8]. Decreased VEGF mRNA expression was
found in the lung of human, premature newborns dying of
BPD [9]. It is also known that VEGF plays a role in heart
morphogenesis including heart septation [10,] and it is
important in the vascular remodelling occurring during
ductus arteriosus closure [11]. Although there are no hu-
man data about the role of VEGF in acute renal failure in
premature infants, it was revealed in an animal experiment,
that anti-VEGF therapy inhibits glomerular development
in newborn mice [12]. These data suggest a potential role
for VEGF in the pathogenesis of perinatal complications.
The VEGF gene is highly polymorphic. Some of these
polymorphic loci have been identified as determinants of
VEGF production. A significant correlation was observed
between genotypes for VEGF G+405C, VEGF C-2578A
SNPs and the production of VEGF in peripheral blood
mononuclear cells [13, 14]. It was also revealed that the
common carrier state of VEGF- 460C and VEGF+405G
alleles in the promoter have a 71% higher basal promoter
activity when compared with the wild-type sequence [15].
In previous studies, we found correlations between VEGF
G+405C polymorphism and the risk of ROP [16], in addi-
tion to the risk of congenital heart disease [17].
doi:10.1684/ecn.2006.0041
Eur. Cytokine Netw., Vol. 17 n° 4, December 2006, 266-70266
Assuming that these polymorphisms could alter the VEGF
producing ability, in the present study we tested whether
the carrier states for VEGF C-2578A, VEGF T-460C and
VEGF G+405C are associated with the risk of preterm
birth and perinatal complications.
PATIENTS AND METHODS
Patients
We enrolled 128 LBW (≤ 1500 grams) infants and 200
healthy, term infants in our retrospective study. All of the
infants were delivered, and LBW infants were treated, at
the Second Department of Gynaecology and Obstetrics,
Semmelweis University, Budapest.
The mean gestational age of the LBW infants was 30 ± 3
weeks and the mean birth weight was 1170 ± 280 grams.
One hundred and eleven infants were single births and 17
were one sibling of 17 twins enrolled. We made subgroups
according to the presence of perinatal complications such
as respiratory distress syndrome (RDS) (n = 60) NEC
(n = 49), IVH (n = 42), ARF (n = 41), BPD (n = 23), per-
sistent ductus arteriosus (PDA) (n = 47) and atrial septal
defect (ASD) (n = 13). Perinatal complications were de-
fined according to internationally accepted criteria [18-
22].
We compared the genotype distributions of LBW infants
with the healthy, term neonates. The mean of gestational
age of the healthy, term neonates was 39±1.1 weeks and
the mean birth weight was 3400±390 grams. We also
compared the genotype distributions of each perinatal
complication subgroup with those LBW infants who did
not suffer any diseases (control groups). The study was
approved by an Institutional Ethical Committee (TUKEB
14/2003).
Genotyping
Dried blood samples taken for metabolic screening after
the 5th postnatal day or at the start of oral feeding were
used for genotyping. DNA was extracted using an agent
(Chelex®, BioRad, Germany) according to the manufac-
turer’s instructions.
VEGF C-2578A and VEGF G+405C SNPs were detected
using the PCR-RFLP method. The PCRs were performed
in a final volume of 50 ll containing 10% 10x PCR buffer,
2mM MgCl2, 0.2 mM dNTPs, 1.5 U Taq DNA polymerase
(Invitrogen, California, USA) and sense and antisense
primers, 0.5 lM of each. The specific primer pairs for
VEGF C-2578A and G+405C were as follows: forward:
5’-GGGCCTTAGGACACCATACC-3’ and reverse: 5’-
TGCCCCAGGGAACAAAGT-3’ and forward: 5’-
CCGACGGCTTGGGGAGATTG-3 and reverse: 5’-
CGGCGGTCACCCCCAAAAG-3’, respectively. The
amplification profile consisted of denaturation at 94 °C for
20s, annealing 57 °C (VEGF C-2578A) or 60 °C (VEGF
G+405C) for 30 s and extension at 72 °C for 30s for 40
amplification cycles. The resultant 267 bp (VEGF
C-2578A) and 197 bp (VEGF G+405C) length products
were digested by Bgl II (VEGF C-2578A) and BsmF I
(VEGF G+405C) at 37 °C or at 65 °C overnight, respec-
tively.
VEGF T-460C SNP was determined by real-time PCR
quantification using fluorescence resonance energy trans-
fer (FRET) hybridisation probes on a Light Cycler system
(Roche Diagnostics, Mannheim, Germany). Primers and
probes were as follows: forward primer: 5’-
AGACGGCAGTCACTAG-3’; reverse primer: 5’-
AATATTGAAGGGGGCAG-3’; one probe (5’-
AGCGGGGAGAAGGCCAGGG-3’) has been labelled at
the 5’ end with the Light Cycler Red 640 fluorophore; the
other one (5’-TGTGGGGTTGAGGGCGTT-3’) has been
labelled at the 3’ end with fluorescein (Tibmolbiol, Berlin,
Germany).
Data analysis
Hardy-Weinberg equilibria of the VEGF C-2578A, VEGF
T-460C and VEGF G+405C SNPs were calculated using
the Arlequin software (http://lgb.unige.ch/arlequin/).
For statistical analysis, the chi-square test was used to
compare allelic and genotype frequencies in LBW infants
and healthy, term neonates, in LBW infants with each
perinatal complication and in corresponding control
groups. For the adjustment for known risk factors of each
perinatal complication, logistic regression analysis was
used to compare allelic and genotype frequencies between
LBW infants with each perinatal complication and corre-
sponding control groups. The level of significance was set
at p < 0.05. All calculations were performed with the sta-
tistical software package SPSS 10.0.
RESULTS
The genotype distribution of the VEGF C-2578A, VEGF
T-460C and VEGF G+405C SNPs fulfilled the Hardy-
Weinberg criteria in all groups (in LBW infants and
healthy, term neonates and in LBW infants with each
perinatal complication, and control groups).
table 1 summarizes the allele frequency and genotype dis-
tribution of VEGF C-2578A, VEGF T-460C and VEGF
G+405C polymorphisms in LBW infants and healthy, term
neonates. The prevalence of the VEGF +405 C allele was
higher in LBW infants than in healthy, term neonates
(p = 0.046, odds ratio [95% CI]: 1.29 [1.01-1.65]).
The prevalence of the VEGF -2578A alleles was higher in
LBW infants with NEC compared with the corresponding
control group (p = 0.049, adjusted odds ratio [95% CI]:
2.77 [1.00-7.65]). This result was adjusted for gestational
age, sepsis, PDA and cardiac failure (CF) (table 2).
We also found that carriers of the VEGF -2578AA geno-
type were significantly fewer among the LBW infants with
ARF than in the corresponding control group (p = 0.021,
adjusted odds ratio [95% CI]: 0.2 [0.05-0.78]); adjusted
for gestational age, sepsis, NEC, RDS, PDA, CF (table 2).
DISCUSSION
VEGF is a key regulator of vascular permeability and
angiogenesis, and regulates multiple endothelial cell func-
tions. VEGF induces endothelial cell proliferation [23],
migration [24] and differentiation [25], and stimulates
endothelial cell survival [26]. Owing to its angiogenic and
mitogenic properties, VEGF is essential in embryonic de-
VEGF polymorphisms in preterm infants 267
velopment [27]. It was demonstrated that knock-out mice
lacking only a single VEGF allele died on the 10th embry-
onic day because of the severely impaired formation of
blood vessels [28].
Foetal genetic predisposition toward preterm birth has
been widely investigated. In line with previous data sug-
gesting the role of foetal genetic background in the aetiol-
ogy of preterm birth, we found that prevalence of a mutant
VEGF+405C allele is significantly higher in LBW infants
than in healthy, term neonates. It is conceivable that the
functional polymorphism of VEGF may influence prema-
turity by the alteration of VEGF production. Watson et al.
demonstrated that in the presence of the VEGF+405CC
genotype, the peripheral blood mononuclear cells pro-
duced less VEGF than those with the GG genotype [13].
We found that carriers of the VEGF+405 C allele, who are
predisposed to low VEGF-producing ability have in-
creased susceptibility to prematurity.
Considering that VEGF is essential for embryonic devel-
opment, we can hypothesize that the decreased ability to
synthesiseVEGF could be an important component among
the multiple aetiological factors of prematurity. However,
we tested only the infants’ genotype, and not the maternal
genotype. Since half of the alleles in the newborn originate
from the mother, we can only speculate whether this asso-
ciation is attributable to the infants’ genotype, or the result
of the mother’s genotype. For this reason, further studies
including the father, as well as the mother and the newborn,
should be done to determine the importance of the VEGF
G+405C polymorphism to preterm birth.
We also found that the carrier state for the VEGF-2578A
allele is associated with more frequent development of
NEC. Similarly to polymorphism of VEGF+405, VEGF-
2578 is also associated with the regulation of VEGF syn-
thesis; greater VEGF production was described in the
peripheral blood mononuclear cells in those with the CC
Table 1
Vascular endothelial growth factor (VEGF) genetic polymorphisms in LBW infants and in healthy, term neonates. Birth weight and gestational
age are presented as mean±SD
Low birth weight infants Healthy term neonates
N 128 200
Gender (male/female) 6/62 99/101
Birth weigth mean (SD) grams 1170 ± 280 3400 ± 390
Gestional age mean (SD) weeks 30 ± 3 39 ± 1.1
VEGF C2578 A genotypes
CC/CA/AA 28/60/26 39/91/43
prevalence of A allele 49 51
VEGF T460 C genotypes
TT/TC/CC 31/68/29 19/64/30
prevalence of C allele 49 55
VEGF G+405 C genotypes
GG/GC/CC 58/56/7 75/38/8
prevalence of C allele 29* 22
* Chi-square test: p=0.046, odds ratio [95%CI]: 1.29[1.04-1.165].
Table 2
Vascular endothelial growth factor (VEGF) genetic polymorphisms in perinatal complications. (RDS: respiratory distress syndrome, NEC:
enterocolitis necrotisans, IVH: intraventricular haemorraghia, ARF: acute renal failure, BPD: bronchopulmonary dysplasia, PDA: persistent
ductus arteriosus, ASD: atrial septal defect)
VEGF C2578 A genotypes
CC/CA/AA
prevalence of A allele (%)
VEGF T460 C genotypes
TT/TC/CC
prevalence of C allele (%)
VEGF G+405 C genotypes
GG/GC/CC
prevalence of C allele (%)
Perinatal complication Complication
present
Complication
absent
Complication
present
Complication
absent
Complication
present
Complication
absent
RDS (n=60 out of 124) 14/33/13
48
16/3315
49
15/31/14
49
15/34/15
50
26/32/2
60
33/26/5
29
NEC (n=49 out of 125) 6/27/16
59*
24/40/12
41
9/27/13
54
21/39/16
47
23/25/1
27
37/33/6
30
IVH (n=42 out of 125) 10/24/8
49
22/42/12
49
10/23/9
49
2043/20
50
19/21/2
30
41/37/5
28
ARF (n=41 out of 107) 10/27/4**
43
19/28/19
50
11/237/
45
17/32/17
50
21/18/2
28
30/32/4
30
BPD (n=23 out of 125) 3/15/5
55
28/52/22
47
6/13/4
46
23/53/26
50
13/9/1
25
47/48/7
30
PDA (n=47 out of 125) 10/24/13
52
20/43/15
46
8/25/14
56
22/41/15
46
25/20/2
26
35/37/6
30
ASD (n=13 out of 110) 4/6/3
46
23/53/21
49
4/7/2
42
22/52/23
50
6/7/0
27
46/44/7
30
* Logistic regression analysis: p = 0.049, adjusted odds ratio [95% CI]: 2.77 [1.00-7.65]. ** Logistic regression analysis: p = 0.021, adjusted odds ratio [95% CI]: 0.2
[0.05-0.78].
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genotype than those with AA genotype [14]. Our findings
indicate that the carrier state for the VEGF-2578 mutant
allele, which predisposes to low VEGF production, may
enhance the susceptibility to NEC. The release of vasocon-
strictor agents and proinflammatory cytokines in the small
intestine are central processes in the pathogenesis of NEC
[29]. Several lines of evidence support the notion that
VEGF is involved in the regulation of the vasoconstriction-
vasodilatation equilibrium and it also exerts anti-
inflammatory effects [5, 30]. Although there are no data
about the role ofVEGF in the pathogenesis of NEC, we can
speculate that these effects of VEGF may account for the
association between the carrier state for the VEGF-2578
mutant allele, which predisposes to low VEGF production
and the increased predisposition to NEC.
Interestingly, among the LBW infants with ARF, there
were significantly fewer carriers of the VEGF-2578 AA
genotype, which predisposes to low VEGF synthesis, than
in the corresponding control group. It is known that VEGF
is implicated in the pathogenesis of acute renal failure. It
was demonstrated that VEGF synthesis is up-regulated in
ARF induced by ischemia-reperfusion injury [31]. VEGF
has an important role in maintaining the integrity of the
glomerular filtration barrier, as inhibition ofVEGF activity
may lead to proteinuria [32]. It was observed that exog-
enous VEGF administration promotes endothelial cell pro-
liferation and stabilizes renal function in a remnant kidney
model [33]. Our findings may suggest that the carrier state
of the VEGF-2578 AA genotype predisposing to low
VEGF production has a possible protective effect in the
development of ARF.
In the present study, we also investigated the association
between VEGF SNPs and the risk of congenital heart
disease. Interestingly, in contrast to our previous study [17]
we did not find an association between the carrier state for
VEGF G+405C and VEGF C-2578A and the risk of PDA
or ASD.
A possible explanation for the different results could be the
different populations investigated in the studies. In the
earlier study, we enrolled a larger population of children
who suffered from congenital heart defects (n = 102) as
opposed to the present study where a smaller LBW popu-
lation (n = 60) was investigated. Moreover, in our previous
study we enrolled children between the ages of 2 and 10
years as opposed to the present study where we investi-
gated a population of preterm infants.
However, when evaluating the association between the
VEGF genotype and perinatal complications, it should be
taken in account that the subgroups studied were small.
It is also conceivable that the observed associations be-
tween VEGF G+405C and VEGF C-2578A, preterm birth
and complications such as NEC and ARF are not directly
related to VEGF production capacity. The VEGF gene is
located near to other genes (e.g. heat shock protein 70 [34],
TNF-alpha [35], on chromosome 6 and which are possibly
implicated in preterm birth). Therefore, it is possible that
the association between the SNPs investigated and preterm
birth and its complications are the result of linkage dis-
equilibrium with other gene mutations.
In conclusion, we observed a higher prevalence of the
VEGF +405C allele in LBW infants than in healthy, term
neonates suggesting that the carrier state of this allele is a
risk factor for preterm birth. Furthermore, we found an
association between the carrier state for the VEGF-2578A
allele and the development of NEC in LBW infants. Inter-
estingly, our study also suggests that the VEGF-2578AA
genotype may have a protective role against ARF in LBW
infants. These findings suggest that testing forVEGF SNPs
would provide valuable information for the risk assess-
ment of preterm birth and perinatal complications. How-
ever, because of the relatively small numbers in our study,
the clinical significance of our results may be questioned,
therefore it would be reasonable to extend the investigation
using a larger population to determine VEGF levels.
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